Lanza G, Maestri I, Dubini A, Gafa R, Santini A, Ferretti S, Cavazzini L
Department of Pathology, University of Ferrara, Italy.
Am J Clin Pathol. 1996 May;105(5):604-12. doi: 10.1093/ajcp/105.5.604.
p53 protein expression was evaluated in a series of 204 primary colorectal adenocarcinomas by immunohistochemistry using frozen tissue sections and monoclonal antibody DO-7. Nuclear staining of more than 5% of neoplastic cells was observed in 124 (60.8%) adenocarcinomas, which were classified as p53 positive. p53 immunoreactivity was found to he unrelated to several clinical and pathologic variables, including age and sex of patient, tumor site, tumor stage, grade of differentiation, pattern of growth, degree of peritumoral lymphocytic infiltration, and venous invasion. A strong association was demonstrated between p53 immunostaining and tumor type. Only 4 of 21 mucinous carcinomas examined (19%) were p53 positive. Conversely, 120 of 183 (65.6%) nonmucinous adenocarcinomas showed positive p53 immunostaining (P <.0001). p53 expression also was related to the flow cytometric DNA ploidy pattern, aneuploid carcinomas with DI >1.20 showing higher frequency of p53 overexpression than DNA diploid, and aneuploid tumors with DI < or = 1.20 (P = .0003). No relationship was found between p53 expression and the Ki-67 proliferation index. With respect to the total study population (mean follow-up 33.4 months; range 19-47 months) the duration of overall survival was independent of p53 expression. In the group of 141 patients with stage I, stage II, and stage III disease who had undergone curative resection, positive p53 immunostaining was associated with poorer overall survival (P = .029). Subgroup analysis showed that the reduced survival conferred by p53 overexpression was confined to patients with stage III tumors (P = .027). However, in multivariate analysis, p53 expression failed to demonstrate independent prognostic significance. Our results indicate that immunohistochemical analysis of p53 expression provides valuable information for the understanding of colorectal cancer biology and clinical behavior.
采用冷冻组织切片和单克隆抗体DO-7，通过免疫组织化学方法对204例原发性结肠直肠癌进行p53蛋白表达评估。在124例（60.8%）腺癌中观察到超过5%的肿瘤细胞核染色，这些腺癌被归类为p53阳性。发现p53免疫反应性与几个临床和病理变量无关，包括患者的年龄和性别、肿瘤部位、肿瘤分期、分化程度、生长模式、肿瘤周围淋巴细胞浸润程度和静脉侵犯。p53免疫染色与肿瘤类型之间存在强烈关联。在21例黏液腺癌中仅有4例（19%）p53阳性。相反，183例非黏液腺癌中有120例（65.6%）p53免疫染色呈阳性（P<0.0001）。p53表达还与流式细胞术DNA倍体模式有关，DI>1.20的非整倍体癌显示p53过表达频率高于DNA二倍体癌，以及DI≤1.20的非整倍体肿瘤（P = 0.0003）。未发现p53表达与Ki-67增殖指数之间存在关联。就整个研究人群（平均随访33.4个月；范围19 - 47个月）而言，总生存期与p53表达无关。在141例接受根治性切除的I期、II期和III期疾病患者组中，p53免疫染色阳性与较差的总生存期相关（P = 0.029）。亚组分析显示，p53过表达导致的生存期缩短仅限于III期肿瘤患者（P = 0.027）。然而，在多变量分析中，p53表达未能显示出独立的预后意义。我们的结果表明，p53表达的免疫组织化学分析为理解结肠直肠癌生物学和临床行为提供了有价值的信息。
